Clinical Study on the Effect of Removal of Porphyromonas Gingivalis on Prognosis of Esophageal Cancer After Radical Surgery
NCT06418945 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500
Last updated 2024-05-17
Summary
Esophagectomy is an important means of radical treatment of esophageal cancer, but due to local recurrence and metastasis, the 5-year survival rate of patients with esophageal cancer is only 20-30%. Studies have reported that about 50% of patients relapse within 1 year after surgery, and the short-term recurrence rate is high. Therefore, reducing the recurrence rate of esophageal cancer after operation is an important way to improve its prognosis. Porphyromonas gingivalis infection in ESCC tissues was significantly higher than that in paracancer tissues, and was significantly positively correlated with cancer cell differentiation, lymph node metastasis, TNM stage, and shortened survival of ESCC patients. In summary, porphyromonas gingivalis plays an important role in postoperative recurrence of esophageal cancer. Elimination of porphyromonas gingivalis can significantly reduce the recurrence rate of esophageal cancer after operation. Tinidazole is a class of nitroimidazole drugs. It has been pointed out that the pharmacological mechanism of Tinidazole is to inhibit the DNA synthesis of pathogenic bacteria, so as to eliminate bacteria in periodontal tissues and inhibit local inflammation. Based on this, we designed and fabricated a novel oral microneedle patch loaded with tinidazole. Tinidazole oral microneedle patch can effectively remove porphyromonas gingivalis and promote the repair of gingival tissue. In this study, based on the combination of mechanical removal and antibacterial treatment, a combination of ultrasonic dental cleaning and tinidazole oral composite microneedle patch was designed to completely remove porphyromonas gingivalis in oral cavity, and to evaluate the effect of removal of porphyromonas gingivalis in oral cavity on the prognosis of esophageal cancer after radical surgery.
Conditions
- Evaluate the DFS of Patients With Esophageal Cancer Who Underwent Radical Operation After Regular Removal of Porphyromonas Gingivalis
Interventions
- COMBINATION_PRODUCT
-
Tinidazole oral microneedle patch
Ultrasonic teeth cleaning: After gargling with compound chlorhexidine gargle or 3% hydrogen peroxide gargle for 1 minute, the teeth were cleaned by ultrasonic wave. After the teeth were cleaned, the wound was rinsed with 3% hydrogen peroxide to stop bleeding. Immediately after the ultrasonic cleaning, two pieces of tinidazole oral composite microneedle patch were applied to the upper and lower gums close to the inside of the first molar, especially on the tooth loss or damage, and the mouth was kept closed for 15 minutes. After the microneedle was fully degraded, the room could be left.
Sponsors & Collaborators
-
The First Affiliated Hospital of Henan University of Science and Technology
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-08-01
- Primary Completion
- 2026-12-31
- Completion
- 2027-12-31
More Related Trials
-
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
NCT04974047 ·Status: COMPLETED ·Phase: PHASE2
-
A Comparative Study of Endoscopic Submucosal Dissection and Photodynamic Therapy for Early Esophageal Cancer
NCT05208775 ·Status: UNKNOWN ·Phase: NA
-
Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology
NCT07161453 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma
NCT06429865 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma
NCT06690476 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer
NCT03611712 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO
NCT04137679 ·Status: UNKNOWN ·Phase: PHASE2
-
A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma
NCT05432219 ·Status: UNKNOWN ·Phase: NA
-
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
NCT06122493 ·Status: RECRUITING ·Phase: PHASE2
-
Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)
NCT05603065 ·Status: UNKNOWN ·Phase: PHASE4
-
Submucosal Saline Injection Followed by Endoscopic Ultrasound
NCT06022978 ·Status: UNKNOWN ·Phase: NA
-
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
NCT05469061 ·Status: UNKNOWN ·Phase: PHASE2
-
Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients
NCT05596890 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma;
NCT01745107 ·Status: UNKNOWN ·Phase: PHASE3
-
Intermittent Oro-esophageal Tube Feeding in Late Dysphagia for Nasopharyngeal Carcinoma
NCT06248879 ·Status: WITHDRAWN ·Phase: NA
-
Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
NCT06602843 ·Status: RECRUITING ·Phase: NA
-
The Efficacy of Immunodetection Point Inhibitors for Advanced Esophageal Cancer
NCT04074447 ·Status: UNKNOWN
-
The Microbiome of Oesophageal Squamous Cell Carcinoma
NCT04425122 ·Status: UNKNOWN
-
A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer
NCT06398405 ·Status: RECRUITING ·Phase: PHASE2
-
Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer
NCT01605305 ·Status: COMPLETED ·Phase: PHASE2
-
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
NCT07046221 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Multimodal Endoscopic Image Fusion for Assessing Infiltration in Superficial Esophageal Squamous Cell Carcinoma
NCT06412419 ·Status: NOT_YET_RECRUITING
-
Chemotherapy for Potentially Resectable Locally Advanced Esophagogastric Junction Carcinoma
NCT03211377 ·Status: UNKNOWN
-
Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma
NCT01472419 ·Status: COMPLETED
-
Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection
NCT06161909 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3